Research Article
Targeting the EZH2-PPAR Axis Is a Potential Therapeutic Pathway for Pancreatic Cancer
Figure 2
Effects of combination of bezafibrate and GSK126 on cell viability of PANC-1 and AsPC-1. (a) Effects of different concentrations of bezafibrate, GSK126, and their combination on cell viability of PANC-1 after 120 h treatment. Combination indexes were calculated accordingly on the indicated concentrations of bezafibrate and GSK126. (b) Effects of different concentrations of bezafibrate, GSK126, and their combination on cell viability of PANC-1 after 120 h treatment. Combination indexes were calculated accordingly on the indicated concentrations of bezafibrate and GSK126. The values were expressed as the ( for each group). vs. the bezafibrate group; # vs. the GSK126 group.
(a) |
(b) |